赛伦生物(688163.SH)2025年度归母净利润5171.35万元，同比增长16.76%

Core Viewpoint - Sirun Biotech (688163.SH) reported a slight increase in total revenue for 2025, with a net profit growth attributed to various factors including reduced R&D expenses and changes in investment valuations [1] Financial Performance - The total revenue for 2025 reached 196 million yuan, representing a year-on-year growth of 0.66% [1] - The net profit attributable to the parent company was 51.71 million yuan, showing a year-on-year increase of 16.76% [1] - The gross profit margin remained stable, indicating consistent profitability despite the modest revenue growth [1] Product Development - The anti-rabies serum launched in the second half of 2025 is still in the early stages of sales and has not yet made a significant contribution to revenue during the reporting period [1] Investment and Financial Adjustments - The increase in net profit was primarily due to the recognition of investment losses in the joint venture Shanghai Saiyuan Biotech Co., Ltd. in 2024, along with full impairment provisions for long-term equity investments [1] - There was a decrease in non-recurring gains and losses compared to the previous period, contributing to the overall profit increase [1] - R&D expenses also saw a year-on-year reduction, further supporting the profit growth [1]